These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 22019703)

  • 1. IL-15:IL-15 receptor alpha superagonist complex: high-level co-expression in recombinant mammalian cells, purification and characterization.
    Han KP; Zhu X; Liu B; Jeng E; Kong L; Yovandich JL; Vyas VV; Marcus WD; Chavaillaz PA; Romero CA; Rhode PR; Wong HC
    Cytokine; 2011 Dec; 56(3):804-10. PubMed ID: 22019703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of IL-15/IL-15Rα sushi domain-IgG4 Fc complexes in Pichia pastoris with potent activities and prolonged half-lives.
    Xu H; Shi M; Shao C; Li H; Wu J; Yu Y; Fang F; Guo Y; Xiao W
    Microb Cell Fact; 2021 Jun; 20(1):115. PubMed ID: 34107983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Novel Fusion of ALT-803 (Interleukin (IL)-15 Superagonist) with an Antibody Demonstrates Antigen-specific Antitumor Responses.
    Liu B; Kong L; Han K; Hong H; Marcus WD; Chen X; Jeng EK; Alter S; Zhu X; Rubinstein MP; Shi S; Rhode PR; Cai W; Wong HC
    J Biol Chem; 2016 Nov; 291(46):23869-23881. PubMed ID: 27650494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel human interleukin-15 agonists.
    Zhu X; Marcus WD; Xu W; Lee HI; Han K; Egan JO; Yovandich JL; Rhode PR; Wong HC
    J Immunol; 2009 Sep; 183(6):3598-607. PubMed ID: 19710453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IL-15 superagonist/IL-15RαSushi-Fc fusion complex (IL-15SA/IL-15RαSu-Fc; ALT-803) markedly enhances specific subpopulations of NK and memory CD8+ T cells, and mediates potent anti-tumor activity against murine breast and colon carcinomas.
    Kim PS; Kwilas AR; Xu W; Alter S; Jeng EK; Wong HC; Schlom J; Hodge JW
    Oncotarget; 2016 Mar; 7(13):16130-45. PubMed ID: 26910920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preassociation of IL-15 with IL-15R alpha-IgG1-Fc enhances its activity on proliferation of NK and CD8+/CD44high T cells and its antitumor action.
    Dubois S; Patel HJ; Zhang M; Waldmann TA; Müller JR
    J Immunol; 2008 Feb; 180(4):2099-106. PubMed ID: 18250415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a recombinant human IL-15·sIL-15Rα/Fc superagonist with improved half-life and its antitumor activity alone or in combination with PD-1 blockade in mouse model.
    Zhao M; Luo M; Xie Y; Jiang H; Cagliero C; Li N; Ye H; Wu M; Hao S; Sun T; Yang H; Zhang M; Lin T; Lu H; Zhu J
    Biomed Pharmacother; 2019 Apr; 112():108677. PubMed ID: 30798123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and characterization of a protein superagonist of IL-15 fused with IL-15Rα and a high-affinity T cell receptor.
    Stone JD; Chervin AS; Schreiber H; Kranz DM
    Biotechnol Prog; 2012; 28(6):1588-97. PubMed ID: 22961781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IL-15R alpha-IgG1-Fc enhances IL-2 and IL-15 anti-tumor action through NK and CD8+ T cells proliferation and activation.
    Wu Z; Xu Y
    J Mol Cell Biol; 2010 Aug; 2(4):217-22. PubMed ID: 20671116
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IL-15 superagonist N-803 improves IFNγ production and killing of leukemia and ovarian cancer cells by CD34
    Van der Meer JMR; Maas RJA; Guldevall K; Klarenaar K; de Jonge PKJD; Evert JSH; van der Waart AB; Cany J; Safrit JT; Lee JH; Wagena E; Friedl P; Önfelt B; Massuger LF; Schaap NPM; Jansen JH; Hobo W; Dolstra H
    Cancer Immunol Immunother; 2021 May; 70(5):1305-1321. PubMed ID: 33140189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New interleukin-15 superagonist (IL-15SA) significantly enhances graft-versus-tumor activity.
    Bailey CP; Budak-Alpdogan T; Sauter CT; Panis MM; Buyukgoz C; Jeng EK; Wong HC; Flomenberg N; Alpdogan O
    Oncotarget; 2017 Jul; 8(27):44366-44378. PubMed ID: 28574833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Soluble interleukin-15 receptor alpha (IL-15R alpha)-sushi as a selective and potent agonist of IL-15 action through IL-15R beta/gamma. Hyperagonist IL-15 x IL-15R alpha fusion proteins.
    Mortier E; Quéméner A; Vusio P; Lorenzen I; Boublik Y; Grötzinger J; Plet A; Jacques Y
    J Biol Chem; 2006 Jan; 281(3):1612-9. PubMed ID: 16284400
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the biological activities of the IL-15 superagonist complex, ALT-803, following intravenous versus subcutaneous administration in murine models.
    Liu B; Jones M; Kong L; Noel T; Jeng EK; Shi S; England CG; Alter S; Miller JS; Cai W; Rhode PR; Wong HC
    Cytokine; 2018 Jul; 107():105-112. PubMed ID: 29452720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunobiology of the IL-15/IL-15Rα complex as an antitumor and antiviral agent.
    Guo Y; Luan L; Patil NK; Sherwood ER
    Cytokine Growth Factor Rev; 2017 Dec; 38():10-21. PubMed ID: 28888485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NKTR-255, a novel polymer-conjugated rhIL-15 with potent antitumor efficacy.
    Miyazaki T; Maiti M; Hennessy M; Chang T; Kuo P; Addepalli M; Obalapur P; Sheibani S; Wilczek J; Pena R; Quach P; Cetz J; Moffett A; Tang Y; Kirk P; Huang J; Sheng D; Zhang P; Rubas W; Madakamutil L; Kivimäe S; Zalevsky J
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34001523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A homodimeric IL-15 superagonist F4RLI with easy preparation, improved half-life, and potent antitumor activities.
    Lv L; Wang H; Shi W; Wang Y; Zhu W; Liu Z; Chen X; Zheng C; Kong W; Li W; Zhu J; Lu H
    Appl Microbiol Biotechnol; 2022 Nov; 106(21):7039-7050. PubMed ID: 36184689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IL-15 superagonist RLI has potent immunostimulatory properties on NK cells: implications for antimetastatic treatment.
    Desbois M; Béal C; Charrier M; Besse B; Meurice G; Cagnard N; Jacques Y; Béchard D; Cassard L; Chaput N
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32532840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Converting IL-15 to a superagonist by binding to soluble IL-15R{alpha}.
    Rubinstein MP; Kovar M; Purton JF; Cho JH; Boyman O; Surh CD; Sprent J
    Proc Natl Acad Sci U S A; 2006 Jun; 103(24):9166-71. PubMed ID: 16757567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increasing the biological activity of IL-2 and IL-15 through complexing with anti-IL-2 mAbs and IL-15Rα-Fc chimera.
    Votavova P; Tomala J; Kovar M
    Immunol Lett; 2014; 159(1-2):1-10. PubMed ID: 24512738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The exon-3-encoded domain of IL-15ralpha contributes to IL-15 high-affinity binding and is crucial for the IL-15 antagonistic effect of soluble IL-15Ralpha.
    Bouchaud G; Garrigue-Antar L; Solé V; Quéméner A; Boublik Y; Mortier E; Perdreau H; Jacques Y; Plet A
    J Mol Biol; 2008 Sep; 382(1):1-12. PubMed ID: 18656487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.